Osteoporosis International

, Volume 19, Issue 8, pp 1185–1192 | Cite as

Link between obstructive sleep apnea and increased bone resorption in men

  • H. Tomiyama
  • R. Okazaki
  • D. Inoue
  • H. Ochiai
  • K. Shiina
  • Y. Takata
  • H. Hashimoto
  • A. Yamashina
Original Article



The bone metabolic abnormalities in patients with obstructive sleep apnea (OSA) were examined. Severity-dependent increases in the serum/urinary levels of bone resorption markers and their attenuation following continuous positive airway pressure therapy in subjects with OSA provide the first evidence of a link between OSA and abnormal bone metabolism.


Hypoxia, microinflammation and oxidative stress, well-known pathophysiological features of obstructive sleep apnea (OSA), are also known to affect bone metabolism. We examined the bone metabolic abnormalities in patients with OSA and also the effects of continuous positive airway pressure (CPAP) therapy on these abnormalities.


A cross-sectional and prospective study was conducted in 50 consecutive male subjects visiting a sleep clinic and 15 age-matched control subjects without OSA. Plasma concentrations of IL-1β, IL-6, TNF-alfa, 3-nitrotyrosine, osteocalcin, bone-specific alkaline phosphatase (BAP), and urinary concentrations of cross-linked C-terminal telopeptide of type I collagen (CTX) were examined before and after 3 months’ CPAP in subjects with OSA.


The plasma levels of the cytokines as well as the urinary CTX levels were higher in subjects with severe OSA than in those with mild OSA or control subjects. Significant decrease of the urinary excretion of CTX (before: 211 ± 107 vs. after: 128 ± 59 μg/mmol/creatinine; p < 0.01) as well as of the plasma levels of the cytokines was observed following 3 months’ CPAP.


Severity-dependent increases in the serum/urinary levels of bone resorption markers and their reversal following CPAP in subjects with OSA provide the first evidence of a link between OSA and abnormal bone metabolism.


Bone metabolic markers Hypoxia Osteopenia Sleep apnea 


  1. 1.
    Collop NA (2005) Obstructive sleep apnea syndromes. Semin Respir Crit Care Med 26:13–24PubMedCrossRefGoogle Scholar
  2. 2.
    Caples SM, Gami AS, Somers VK (2005) Obstructive sleep apnea. Ann Intern Med 142:187–97PubMedGoogle Scholar
  3. 3.
    Shamsuzzaman AS, Gersh BJ, Somers VK (2003) Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290:1906–1914PubMedCrossRefGoogle Scholar
  4. 4.
    Hatipoglu U, Rubinstein I (2003) Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 70:665–671PubMedCrossRefGoogle Scholar
  5. 5.
    Schulz R, Mahmoudi S, Hattar K et al (2000) Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 162:566–570PubMedGoogle Scholar
  6. 6.
    Becker HF, Jerrentrup A, Ploch T et al (2003) Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107:68–73PubMedCrossRefGoogle Scholar
  7. 7.
    Pepperell JC, Ramdassingh-Dow S, Crosthwaite N et al (2002) Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: a randomised parallel trial. Lancet 359:204–210PubMedCrossRefGoogle Scholar
  8. 8.
    Marin JM, Carrizo SJ, Vicente E et al (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046–1053PubMedGoogle Scholar
  9. 9.
    Doherty LS, Kiely JL, Swan V et al (2005) Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 127:2076–2084PubMedCrossRefGoogle Scholar
  10. 10.
    Young T, Palta M, Dempsey J et al (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235PubMedCrossRefGoogle Scholar
  11. 11.
    Papaioannou A, Parkinson W, Ferko N et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14:913–917PubMedCrossRefGoogle Scholar
  12. 12.
    Arnett TR, Gibbons DC, Utting JC et al (2003) Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol 196:2–8PubMedCrossRefGoogle Scholar
  13. 13.
    Basu S, Michaelsson K, Olofsson H et al (2001) Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 288:275–279PubMedCrossRefGoogle Scholar
  14. 14.
    Clowes JA, Riggs BL, Khosla S (2005) The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 208:207–227PubMedCrossRefGoogle Scholar
  15. 15.
    Raisz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115:3318–3325PubMedCrossRefGoogle Scholar
  16. 16.
    Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 22:667–689Google Scholar
  17. 17.
    Shiina K, Tomiyama H, Takata Y et al (2006) Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. Hypertens Res 29:433–441PubMedCrossRefGoogle Scholar
  18. 18.
    Rechtshaffen AK, A (ed) 1968 A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. UCLA Brain Information Service/Brain Research Institute, Los AngelesGoogle Scholar
  19. 19.
    Chaudhary B, Dasti S, Park Y et al (1998) Hour-to-hour variability of oxygen saturation in sleep apnea. Chest 113:719–722PubMedCrossRefGoogle Scholar
  20. 20.
    Sun YC, Chang PY, Tsao KC et al (2007) Establishment of a sandwich ELISA using commercial antibody for plasma or serum 3-nitrotyrosine (3NT). Elevation in inflammatory diseases and complementary between 3NT and myeloperoxidase. Clin Chim Acta 378:175–180PubMedCrossRefGoogle Scholar
  21. 21.
    Utting JC, Robins SP, Brandao-Burch A et al (2006) Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 312:1693–1702PubMedCrossRefGoogle Scholar
  22. 22.
    Miller RG, Segal JB, Ashar BH et al (2006) High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol 81:236–241PubMedCrossRefGoogle Scholar
  23. 23.
    Ionescu AA, Schoon E (2003) Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J Suppl 46:64s–75sPubMedCrossRefGoogle Scholar
  24. 24.
    Mineo TC, Ambrogi V, Mineo D et al (2005) Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 127:1960–1966PubMedCrossRefGoogle Scholar
  25. 25.
    Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both. Am J Med 119:S25–31PubMedCrossRefGoogle Scholar
  26. 26.
    Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281–294PubMedCrossRefGoogle Scholar
  27. 27.
    Ueda M, Inaba M, Okuno S et al (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77:1130–1139PubMedCrossRefGoogle Scholar
  28. 28.
    Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660–2667PubMedCrossRefGoogle Scholar
  29. 29.
    Alam I, Lewis K, Stephens JW, Baxter JN (2007) Obesity, metabolic syndrome and sleep apnea: all pro-inflammatory states. Obes Rev 8:119–127PubMedCrossRefGoogle Scholar
  30. 30.
    Vgontzas AN, Pejovic S, Zoumakis E et al (2007) Hypothalamic-pituitary-adrenal axis activity in obese men with and without sleep apnea: effects of continuous positive airway pressure therapy. J Clin Endocrinol Metab 92:4199–4207PubMedCrossRefGoogle Scholar
  31. 31.
    Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab. 11:79–85PubMedCrossRefGoogle Scholar
  32. 32.
    Tanaka S, Nakamura K, Takahasi N et al (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208:30–49PubMedCrossRefGoogle Scholar
  33. 33.
    Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018PubMedCrossRefGoogle Scholar
  34. 34.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRefGoogle Scholar
  35. 35.
    Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRefGoogle Scholar
  36. 36.
    Bravo Mde L, Serpero LD, Barcelo A, Barbe F, Agusti A, Gozal D (2007) Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. Sleep Breath 11:177–185PubMedCrossRefGoogle Scholar
  37. 37.
    Yokoe T, Minoguchi K, Matsuo H et al (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107:1129–1134PubMedCrossRefGoogle Scholar
  38. 38.
    Tomlinson JW, Bujalska I, Stewart PM, Cooper MS (2000) The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res 26:711–722PubMedCrossRefGoogle Scholar
  39. 39.
    Fulkerson JA, Himes JH, French SA et al (2004) Bone outcomes and technical measurement issues of bone health among children and adolescents: considerations for nutrition and physical activity intervention trials. Osteoporos Int 15:929–941PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • H. Tomiyama
    • 1
  • R. Okazaki
    • 2
  • D. Inoue
    • 2
  • H. Ochiai
    • 2
  • K. Shiina
    • 1
  • Y. Takata
    • 1
  • H. Hashimoto
    • 3
  • A. Yamashina
    • 1
  1. 1.Second Department of Internal MedicineTokyo Medical UniversityShinjuku-kuJapan
  2. 2.Third Department of Internal MedicineTeikyo University Chiba Medical CenterTokyo Japan
  3. 3.Health Management and PolicyUniversity of Tokyo Graduate School of MedicineTokyoJapan

Personalised recommendations